The Aicardi Goutieres Syndrome Advocacy Association (AGSAA) and Transposon Therapeutics, Inc. have joined hands in a new collaboration to educate patients about the new therapeutic opportunity presented by Transposon, incorporate patient needs and preferences into the design of future trials, and recruit for their active clinical trial in Europe. The collaboration strives to prioritize patient perspectives and elevate their voice throughout the trial design process, promoting greater inclusivity in clinical trials for Aicardi-Goutieres Syndrome.
This collaboration will help to educate and inform families about trial procedures, details, and aims using plain language. By bringing together the expertise of both organizations, we can accelerate the development of new treatments for AGS and enhance the care provided to patients and their families.
"We are thrilled to team up with Transposon Therapeutics, Inc. to help AGS families understand new opportunities," said Patrick Winters, Director of Research at AGSAA. "By working together, we can ensure that patient needs and desires are taken into account during clinical trial design and that families have the information they need to make informed decisions about participation in clinical trials."
To get involved and be notified about future developments, interested parties can inquire about the Transposon TPN-101 clinical trial, join the AGSAA patient registry, or subscribe to our mailing list. By working together, we can make a difference in the lives of those affected by Aicardi-Goutieres Syndrome.
For more information, please contact the AGSAA at info@agsaa.org or view the clinical trial details TPN-101 in Aicardi-Goutières Syndrome (AGS).
